The evaluation of serum biomarkers, such as cancer antigen 125 (CA125) for ovarian cancer and human epididymis protein 4 (HE4), provides a non-invasive approach for monitoring disease progression and recurrence, often preceding radiographic evidence of relapse [39,40,41]. This evidence concerns the gene WFDC2 and ovarian cancer.